Emerging host cell targets for hepatitis C therapy
- 31 March 2007
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 12 (5-6) , 209-217
- https://doi.org/10.1016/j.drudis.2007.01.009
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 daysBritish Journal of Cancer, 2006
- The α Isoform of Protein Kinase CKI Is Responsible for Hepatitis C Virus NS5A HyperphosphorylationJournal of Virology, 2006
- Treating viral hepatitis C: efficacy, side effects, and complicationsGut, 2006
- Oxidative stress inhibits IFN-α-induced antiviral gene expression by blocking the JAK–STAT pathwayJournal of Hepatology, 2006
- Diverse Effects of Cyclosporine on Hepatitis C Virus Strain ReplicationJournal of Virology, 2006
- Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811Biochemical and Biophysical Research Communications, 2006
- TLR signalingCell Death & Differentiation, 2006
- Antiviral therapy for chronic hepatitis C: past, present, and futureThe Esophagus, 2006
- Host Heterogeneous Ribonucleoprotein K (hnRNP K) as a Potential Target to Suppress Hepatitis B Virus ReplicationPLoS Medicine, 2005
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Medicine, 2005